Sai Parenteral's Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 3.46x)
- Company maintains a comfortable, low leverage position
CONS
- A large part of profit comes from other income (25.8% of PBT)
- Working capital days have increased from 56 to 707 days
- Total debt has risen sharply - up 85.5% year on year
- Inventory has been piling up - inventory days up from 58 to 96
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| SAIPARENT | 517.95 | 138.65 | 2288.26 | 0.00 | 79.23 | — | 1786.72 | — | 6.10 | 13.16 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| 19 | 57 | 53 | |
| 19 | 44 | 44 | |
| Operating Profit | -0 | 13 | 8 |
| OPM % | -0.26% | 23.28% | 15.95% |
| 1 | 0 | 3 | |
| Interest | 2 | 3 | 4 |
| Depreciation | 1 | 2 | 1 |
| Profit before Tax | 1 | 8 | 12 |
| Tax % | 30.79% | -18.31% | 24.98% |
| Net Profit | 1 | 10 | 9 |
| 0.31 | 3.04 | 2.01 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 97 | 124 | 162 | |
| 78 | 97 | 134 | |
| Operating Profit | 19 | 27 | 28 |
| OPM % | 19.18% | 21.61% | 17.56% |
| 0 | 0 | 5 | |
| Interest | 6 | 7 | 9 |
| Depreciation | 6 | 5 | 6 |
| Profit before Tax | 7 | 14 | 19 |
| Tax % | 36.79% | 28.46% | 10.61% |
| Net Profit | 5 | 10 | 17 |
| EPS | 6.46 | 3.86 | 3.80 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 12%
- Last Year:
- 6%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 7 | 13 | 22 |
| 24 | 78 | 465 | |
| 69 | 65 | 128 | |
| Trade Payables | 22 | 32 | 26 |
| 12 | 27 | 162 | |
| Total Liabilities | 134 | 215 | 803 |
| 44 | 40 | 43 | |
| Capital Work in Progress | 2 | 0 | 1 |
| 0 | 28 | 158 | |
| 13 | 26 | 60 | |
| 0 | 86 | 81 | |
| Cash & Bank | 2 | 1 | 410 |
| 73 | 32 | 50 | |
| Total Assets | 134 | 215 | 803 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -18 | 19 | 112 | |
| Cash from Investing | -17 | -13 | -136 |
| Cash from Financing | 30 | -6 | 433 |
| -8 | -0 | 409 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| PER SHARE | |||
| EPS (₹) | 6.41 | 3.86 | 3.80 |
| Book Value (₹) | 44.02 | 34.27 | 110.23 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 7.26 | 5.93 | 5.11 |
| PROFITABILITY | |||
| Operating Margin % | 19.39% | 21.61% | 17.56% |
| Net Margin % | 4.74% | 8.27% | 10.34% |
| ROE % | 14.56% | 16.76% | 5.80% |
| ROCE % | 12.97% | 16.49% | 7.03% |
| 3.42% | 5.89% | 3.30% | |
| EFFICIENCY | |||
| Debtor Days | 231 | 217 | 189 |
| Inventory Days | 50 | 58 | 96 |
| Payable Days | 140 | 135 | 101 |
| 140 | 139 | 184 | |
| FINANCIAL HEALTH | |||
| Debt to Equity (x) | 2.18x | 0.79x | 0.27x |
| Interest Coverage (x) | 2.27x | 2.97x | 3.14x |
| 1.12x | 1.17x | 2.15x | |
| GROWTH | |||
| Revenue Growth % | 0.00% | 28.38% | 30.57% |
| Operating Profit Growth % | 0.00% | 44.75% | 22.64% |
| Net Profit Growth % | 0.00% | 124.30% | 63.15% |
| 0.00% | -39.74% | -1.70% | |
| VALUATION | |||
| P/E (x) | 0.00x | 0.00x | 0.00x |
| P/B (x) | 0.00x | 0.00x | 0.00x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% |
| 0.00x | 3.09x | -7.65x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-25 - Sai Parenterals Limited has informed the Exchange regarding a press release dated August 25, 2026, titled "Announcement under Regulation 30 (LODR)".
2026-08-25 - Sai Parenterals Limited has informed the Exchange about Bagging/Receiving of orders/contracts
2026-08-25 - Sai Parenterals Limited has informed the Exchange about Schedule of meet
2026-08-20 - Intimation-Newspaper Publication of Notice of 25" Annual General Meeting of the Company for the financial year 2025-26.
2026-08-20 - Submission of Newspaper Publication(s) in PAS-1 for change and variation in the objects of utilization of the Initial Public Offering ( IPO ) proceeds
2026-08-19 - Sai Parenterals Limited has informed the Exchange about Intimation of Book closure and cutoff date for the 25th Annual General Meeting
2026-08-19 - Sai Parenterals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 10, 2026
2026-08-18 - Sai Parenterals Limited has informed the Exchange about Transcript
2026-08-12 - Sai Parenterals Limited has informed the Exchange about Schedule of meet and Link of Recording
News
Recent coverage and analyst commentary for SAIPARENT
Loading news…
AI Stock Analyst
Sai Parenteral's Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account